Leading Medical News of the Day

Your place for beaking medical news and career advice from top medical recruiters

NEW YORK, Aug. 19, 2015 /PRNewswire-USNewswire/ — Today, the Fisher Center for Alzheimer’s Research Foundation is proud to announce they have funded a significant new finding through research conducted by Fisher Center scientists at The Rockefeller University in an effort to find a cure for Alzheimer’s. read more

Novartis drug Odomzo® gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients Basel, August 20, 2015 Novartis announced today that the European Commission has approved Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to curative surgery or radiation therapy[1]. read more

The Leukemia & Lymphoma Society Applauds Encouraging Data From a Phase 2 Study of Venetoclax for a High-Risk Subset of Chronic Lymphocytic Leukemia Patients

WHITE PLAINS, N.Y., Aug. 19, 2015 /PRNewswire-USNewswire/ — The Leukemia & Lymphoma Society (LLS) welcomes the news that an investigational therapy to treat patients with a high-risk subset of chronic lymphocytic leukemia (CLL) has shown very positive results in a Phase II clinical trial. read more

U.S. FDA Accepts BOTOX® (onabotulinumtoxinA) Resubmission for the Treatment of Lower Limb Spasticity in Adults

DUBLIN, Aug. 20, 2015 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults. A six-month review period has been assigned for the sBLA. The Prescription Drug User Fee Act (PDUFA) date is expected to be in the first quarter of 2016. read more

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

RIDGEFIELD, Conn and INDIANAPOLIS, Aug. 20, 2015 /PRNewswire/ — Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from EMPA-REG OUTCOME®. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance® (empagliflozin) in more than 7,000 adults with type 2 diabetes (T2D) at high risk for CV events. EMPA-REG OUTCOME met its primary endpoint and demonstrated superiority of JARDIANCE, when added to standard of care, in CV risk reduction. The primary endpoint was defined as time to first occurrence of either CV death, or non-fatal myocardial infarction or non-fatal stroke. JARDIANCE is the only glucose-lowering agent to have demonstrated CV risk reduction in a dedicated cardiovascular outcomes trial. read more

Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals

Enters Sexual Health Market with FDA-Approved Addyi™ (flibanserin 100mg)
Addyi Expected to Launch in U.S. in the Fourth Quarter of 2015

LAVAL, Quebec and RALEIGH, N.C., Aug. 20, 2015 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones. read more

For leading medical news and career advice subscribe to Med Career News

Shark.tidbits.wht

 

 

 

 

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.